Restoring Balance In The Gut To Prevent Drug-Resistant Infection
Executive Summary
Silvia Caballero, one of In Vivo’s 2020 Rising Leaders, is heading up Vedanta’s efforts to prevent potentially lethal infections stemming from colonization of the gut microbiome with a novel bacterial cocktail that is nearing clinical development.
You may also be interested in...
Vedanta Receives Cash Injection To Proceed With Microbiome-Derived Pipeline
Vedanta’s latest financing allows it to push three of its microbiome-based drug candidates further into the clinic, with big name partners such as BMS and Janssen onboard.
Regenxbio: On The Cusp Of Becoming A Commercial Gene Therapy Player
Partnered with AbbVie on a wet AMD gene therapy, Regenxbio is also advancing wholly owned candidates for Duchenne muscular dystrophy and MPS I and MPS II.
Sanofi ThiNKs Scribe’s CRISPR Approach Can Advance Its NK Cell Therapy Goals
Deal Snapshot: CRISPR-Cas9 co-inventor Jennifer Doudna-founded gene-editing firm inks its second large collaboration, teaming with Sanofi on off-the-shelf natural killer cell therapies for cancer.